Several studies have documented the progression of CD38-targeting antibodies in other hematologic neoplasms, including chronic lymphocytic leukemia, T-cell acute lymphoblastic leukemia, and natural killer (NK)/T-cell lymphoma [42–44]. Here, CD38 is linked to hematopoietic and lymphoid system neoplasm.